Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21825838 | 0.81 | F2 (0.42) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21826394 | 0.81 | F2 (0.48) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21825720 | 0.81 | F2 (0.39) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21826382 | 0.81 | F2 (0.48) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21825722 | 0.81 | F2 (0.39) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21825839 | 0.81 | F2 (0.42) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21963184 | 0.81 | F2 (0.42) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21825683 | 0.80 | F2 (0.44) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL21826733 | 0.80 | F2 (0.44) | F2PLAUKLKB1ELANEKMT2A | |
| SCHEMBL1067129 | 0.80 | F2 (0.41) | F2PLAUKLKB1ELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839927-B | Novel method | 英夫拉索姆有限公司 | 2025-01-03 | — | — | CN | claimed |
| EP-3867231-B1 | NOVEL PROCESSES | INFLAZOME LTD (IE) | 2024-05-01 | — | — | EP | claimed |
| US-11724988-B2 | Processes | INFLAZOME LIMITED (IE) | 2023-08-15 | — | — | US | claimed |
| CN-116396222-A | Synthesis method of Kangafinil intermediate 1- (3-amino-1-isopropyl-1H-pyrazol-4-yl) ethyl-1-ketone | 上海睿腾医药科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20220064125-A1 | NOVEL PROCESSES | INFLAZOME LIMITED (IE) | 2022-03-03 | — | — | US | claimed |
| CN-112839927-A | Novel process | 英夫拉索姆有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-112839927-B | Novel method | 英夫拉索姆有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | F2 4820/4885PLAU 1382/4885KLKB1 2743/4885 |
| US-20220064125-A1 | NOVEL PROCESSES | NLRP3, NOD1, NLRP1 | F2 4250/4885PLAU 2810/4885KLKB1 1395/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | F2 3398/4885PLAU 2289/4885KLKB1 538/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | F2 3398/4885PLAU 2289/4885KLKB1 538/4885 |
| US-11724988-B2 | Processes | NLRP3, NOD1, NLRP1 | F2 3800/4885PLAU 2864/4885KLKB1 1152/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | F2 2844/4885PLAU 1115/4885KLKB1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.